Shahram Ala

Shahram Ala


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
SAShahram Ala
Shahram Ala
MSMajid Saeedi
Majid Saeedi
FEFariborz Eshghi
Fariborz Eshghi
PMParastou Mirzabeygi
Parastou Mirzabeygi
Topical metronidazole (10 percent) has been previously demonstrated to decrease postoperative pain after hemorrhoidectomy. The aim of this study was to evaluate the effect of topical metronidazole (10 percent) in reducing postoperative and after-defecation pain of hemorrhoidectomy. A double-blind, randomized trial was conducted to compare posthemorrhoidectomy pain with use of topical metronidazole (10 percent) vs. placebo carrier, applied to surgical site. Forty-seven patients were randomly allocated to receive metronidazole (n=25) or placebo (n=22). Pain was assessed using a visual analog scale preoperatively and on postoperative hours 6 and 12 and at days 1, 2, 7, and 14. The use of narcotic, additional analgesics, and complications were recorded. (Pain scores were calculated and compared with baseline values and control group (t test, SPSS ver.10). Patients in the topical metronidazole group had significantly less postoperative pain than those in the placebo group up to day 14 (P

11 December 2012 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SAShahram Ala
Shahram Ala
FEFariborz Eshghi
Fariborz Eshghi
REReza Enayatifard
Reza Enayatifard
PFPayam Fazel
Payam Fazel
BRBanafsheh Rezaei
Banafsheh Rezaei
RHRoja Hadianamrei
Roja Hadianamrei

13 May 2020 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
ASAdeleh Sahebnasagh
Adeleh Sahebnasagh
AGArash Ghasemi
Arash Ghasemi
JAJafar Akbari
Jafar Akbari
AAAbbas Alipour
Abbas Alipour
HLHossein Lashkardoost
Hossein Lashkardoost
ESEbrahim Salehifar
Ebrahim Salehifar
Background: Acute radiation-induced proctitis (ARP) is the most common side effect following radiotherapy for malignant pelvic disease. This study evaluated the efficacy of Aloe vera ointment in prevention of ARP. Methods: Forty-two patients receiving external-beam radiotherapy (RT) for pelvic malignancies were randomized to receive either Aloe vera 3% or placebo topical ointment during radiotherapy for 6 weeks. These patients were evaluated based on the severity (grade 0–4) of the following symptoms weekly: rectal bleeding, abdominal/rectal pain, diarrhea, or fecal urgency. RTOG acute toxicity criteria and psychosocial status of the patients were also recorded weekly. Lifestyle impact of the symptoms, and quantitative measurement of C-reactive protein (CRP), an indicator of systemic inflammation, were also measured. Results: The results of present study demonstrated a significant preventive effect for Aloe vera in occurrence of symptom index for diarrhea (p < 0.001), rectal bleeding (p < 0.001), and fecal urgency (p = 0.001). The median lifestyle score improved significantly with Aloe vera during RT (p < 0.001). Intervention patients had a significant lower burden of systemic inflammation as the values for quantitative CRP decreased significantly over 6 weeks of follow-up (p = 0.009). Conclusion: This study showed that Aloe vera topical ointment was effective in prevention of symptoms of ARP in patients undergoing RT for pelvic cancers. Trial registration: IRCT201606042027N6. Registration date: 2016-09-04.

23 March 2016 in Nutrition and Cancer
Verified
Journal Article
Closed access
SAShahram Ala
Shahram Ala
MSMajid Saeedi
Majid Saeedi
GJGhasem Janbabai
Ghasem Janbabai
RGReza Ganji
Reza Ganji
EAElham Azhdari
Elham Azhdari
ASAfshin Shiva
Afshin Shiva
Sucralfate has been used for the prevention and treatment of radiotherapy- and chemotherapy-induced stomatitis and mucositis in a number of studies, but the results are contradictory. To answer such discrepancies, the present study was designed to evaluate the efficacy of sucralfate mouthwash in prevention of 5-fluorouracil (5-FU)-induced oral mucositis in patients with gastrointestinal malignancies. Patients with gastrointestinal cancers receiving 5-FU-based chemotherapy regimens were included in this randomized, blinded, controlled trial and were randomly allocated to either sucralfate mouthwash (every 6 h) or placebo. The patients were visited at fifth and tenth day of trial; the presence and severity of oral mucositis and the intensity of pain were assessed. The patients receiving sucralfate experienced lower frequency and severity of mucositis (76% vs. 38.5%, P = 0.005 and 84 vs. 38.5%, P < 0.001, respectively) and less intense pain (2.5 ± 2.2 vs. 5.08 ± 3.82, P = 0.004 and 1.33 ± 0.86 vs. 4.12 ± 3.5, P = 0.001, respectively) compared with the placebo group both at day 5 and day 10. Within the sucralfate group, a decrease in frequency and severity of mucositis was observed throughout the trial period, while in the placebo group no such effect was observed. Sucralfate mouthwash reduced the frequency and severity of 5-FU-induced oral mucositis in patients with gastrointestinal malignancies compared with placebo, indicating its efficacy in the prevention of chemotherapy-induced mucositis.

1 December 2016 in International Journal of Surgery
Verified
Journal Article
Closed access
MAMina Alvandipour
Mina Alvandipour
SAShahram Ala
Shahram Ala
HTHasan Tavakoli
Hasan Tavakoli
JCJamshid Yazdani- Charati
Jamshid Yazdani- Charati
ASAfshin Shiva
Afshin Shiva
The most frequent problems after anal fistulotomy are pain, bleeding, and delayed or impaired wound healing. Topical Sucralfate preparation has been used to treat a wide variety of wounds. In this study, we investigate effects of 10% sucralfate ointment on wound healing and postoperative pain after fistulotomy. A total of 41 patients undergoing anorectal fistulotomy were included in this randomized, blinded, controlled trial and were randomly allocated to either sucralfate ointment (every 12 h) or placebo. The patients were visited weekly for up to 5 weeks. The intensity of pain and the wound healing were assessed. The sucralfate group had significantly less pain at rest (1.92 ± 0.88 vs 2.96 ± 0.98; P = 0.002) and on defecation (1.68 ± 0.92 vs 3.08 ± 1.12; p < 0.001) than the placebo group from 1st to 5th post-operative visits. Complete wound healing was achieved after 8.15 ± 1 weeks in placebo group versus 5.9 ± 0.8 weeks in sucralfate group (p < 0.001). There were no significant differences in the frequencies of postoperative complications between the two groups. Compared with placebo, sucralfate ointment reduced postoperative pain at rest and on defecation and improves wound healing in patients undergoing fistulotomy.

1 March 2019
Verified
Journal Article
Open access
PDF file
NKNeda Koulaeinejad
Neda Koulaeinejad
KHKaveh Haddadi
Kaveh Haddadi
SESaeid Ehteshami
Saeid Ehteshami
MSMisagh Shafizad
Misagh Shafizad
ESEbrahim Salehifar
Ebrahim Salehifar
SAShahram Ala
Shahram Ala
Traumatic brain injury (TBI) is a public health problem worldwide. Secondary damage of brain injury begins within a few minutes after the trauma and can last a long time. It can be reversible, unlike primary injury. Therefore, therapeutic intervention can be used. The aims of this study were to assess the effects of minocycline on neurological function and serum S100B protein and neuron-specific enolase (NSE) levels in patients with moderate to severe TBI. Patients with acute onset of TBI and surgical evacuation of hematoma were randomized to receive either minocycline 100 mg orally twice daily or placebo for 7 days. The primary outcomes included changes in level of S100B and NSE at different time points during the trial. Additionally, changes in Glasgow coma scale (GCS) score were evaluated. The Glasgow Outcome Scale-Extended (GOS-E) score at 6 month after injury was assessed in discharge patients. Thirty four patients were randomized into the placebo (n=20) and treatment (n=14) groups. There was a marginal statistically significant differences in the normalized value of S100B between groups (p<0.1). The reduction in serum NSE level from baseline to day 5 was statistically significant (p=0.01) in minocycline group while it was not significantly decrease in placebo group (p=0.2). Also, GCS improvement over time within the minocycline group was significant (p=0.04) while was not significant in placebo group (p=0.11). The GOS-E scores were not significantly different between minocycline and placebo group. Based on this study, it seems that the use of minocycline may be effective in acute TBI.